Compare · CNC vs VRDN
CNC vs VRDN
Side-by-side comparison of Centene Corporation (CNC) and Viridian Therapeutics Inc. (VRDN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and VRDN operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $34.83B, about 15.7x VRDN ($2.22B).
- CNC has hit the wire 14 times in the past 4 weeks while VRDN has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Centene Corporation
- Viridian Therapeutics Inc.
- Price
- -
- -
- Market cap
- $34.83B
- $2.22B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 14
- 0
- Recent ratings
- 25
- 25
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Viridian Therapeutics Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Latest CNC
- Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma
- SEC Form 4 filed by Centene Corporation
- PA Health & Wellness Earns National Recognition Among Top Medicaid Health Plans for Second Consecutive Year
- Centene to Launch Nationwide Gold Card Program for Qualifying Providers
- SEC Form 8-K filed by Centene Corporation
- Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri
- Wellcare Unveils 2027 Medicare Offerings Focused on Affordability and Integrated Care
- Director Tyler Lauren M was granted 482 shares, increasing direct ownership by 15% to 3,698 units (SEC Form 4)
- Director Tanji Kenneth was granted 603 shares, increasing direct ownership by 5% to 13,093 units (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 583 shares, increasing direct ownership by 2% to 25,796 units (SEC Form 4)
Latest VRDN
- Chief Legal Officer Tousignant Jennifer sold $348,194 worth of shares (14,212 units at $24.50) and exercised 10,000 shares at a strike of $14.41, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Tripuraneni Radhika exercised 40,000 shares at a strike of $13.21 (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Viridian Therapeutics Inc.
- SEC Form 10-Q filed by Viridian Therapeutics Inc.
- Viridian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
- SEC Form 4 filed by Director Morris Arlene
- SEC Form 4 filed by Director Kiselak Tomas
- SEC Form 4 filed by Director Gheuens Sarah
- SEC Form 4 filed by Director Moses Jennifer K.